Cyban

About

Cyban develops a non-invasive bedside Brain Pulse Oximeter and sensor platform that continuously monitors cerebral oxygenation in ICU patients, providing a real-time alternative to invasive intracranial probes and scans.

Mission

Cyban is building a non-invasive bedside medical device that continuously measures oxygen levels in the brain to help prevent permanent brain damage or death after traumatic brain injury. The device aims to replace invasive probes and reduce medical complications, disability risk, and ICU length of stay, delivering cost savings for hospitals. Breakthrough Victoria is investing $2 million in Cyban as part of a $6.25 million Series A round; Significant Early Venture Capital and InterValley Ventures are also participants. Proceeds from the round will support regulatory submissions in Australia and the United States and fund the start of local manufacturing in Victoria. The company plans to scale commercialization efforts from Victoria and expects the program to create up to 50 new Victorian jobs over the next four years. Quotes in the release emphasize the company’s potential to scale globally and accelerate time to market with this funding. Cyban develops a novel, non-invasive Brain Pulse Oximeter and accompanying sensor platform to monitor brain oxygen levels in ICU patients. The technology aims to provide real-time monitoring as an alternative to eye-dilation checks, expensive brain scans, or invasive intracranial procedures. The device and platform originate from the work of ICU specialist Dr Barry Dixon, who led Intensive Care Research at St Vincent’s Hospital for 15 years. Cyban is focused on commercialisation and using recent funding to finish a go-to-market prototype. The company plans expanded clinical trials in the US and will pursue regulatory clearance ahead of a planned market release in 2024. Cyban recently closed an oversubscribed $5.25M Series A to fund team growth, trials, and regulatory work as it moves toward commercial launch.

Quick Facts